JSPRWJaper Therapeutics Inc. Warrants
0.0120USD-1.64%Mkt Cap: —P/E: —3d ago
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a …
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-75.80M $
Revenue/Share—
Last Price0.0120 USD
Fiscal Year End—
MR Quarter—
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.10
EPS (TTM)-3.84
EPS (Forward)—
52W Range
0.006739% of range0.0204
52W High0.0204 USD
52W Low0.0067 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1826.09%
ROA-211.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.16M $
CapEx (TTM)7.00K $
FCF Margin—
FCF Yield—
Net Debt-13.39M $
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity0.30
Current Ratio2.26
Quick Ratio1.57
Book Value/Sh0.1210 USD
Cash/Share0.5050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float23.31M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta3.03
S&P 52W Chg18.16%
Avg Vol (30d)8.60K
Avg Vol (10d)—
Technical Indicators
RSI (14)31.6
MACD-0.0021
MACD Signal-0.0017
MACD Hist.-0.0004
BB Upper0.0246 USD
BB Middle0.0166 USD
BB Lower0.0085 USD
BB Width97.04%
ATR (14)0.0021 USD
Vol Ratio (20d)1.36x